Ascendis Pharma A/S (BVMF:A1SN34)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of BRL 75.82 billion. The enterprise value is 77.34 billion.

Market Cap	75.82B
Enterprise Value	77.34B

Important Dates

The next estimated earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+4.69%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	61.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	48.25
PS Ratio	16.28
PB Ratio	-72.01
P/TBV Ratio	n/a
P/FCF Ratio	258.17
P/OCF Ratio	217.53
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-52.45
EV / Sales	18.02
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	263.36

Financial Position

The company has a current ratio of 1.04

Current Ratio	1.04
Quick Ratio	0.72
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	19.20
Interest Coverage	-1.69

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-6.86%
Return on Invested Capital (ROIC)	-11.67%
Return on Capital Employed (ROCE)	-58.44%
Weighted Average Cost of Capital (WACC)	6.94%
Revenue Per Employee	3.92M
Profits Per Employee	-1.24M
Employee Count	1,189
Asset Turnover	0.58
Inventory Turnover	0.32

Taxes

In the past 12 months, Ascendis Pharma has paid 99.48 million in taxes.

Income Tax	99.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.56% in the last 52 weeks. The beta is 0.49, so Ascendis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.49
52-Week Price Change	+35.56%
50-Day Moving Average	66.22
200-Day Moving Average	n/a
Relative Strength Index (RSI)	57.32
Average Volume (20 Days)	262

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.64

Income Statement

In the last 12 months, Ascendis Pharma had revenue of BRL 4.66 billion and -1.47 billion in losses. Loss per share was -24.33.

Revenue	4.66B
Gross Profit	4.04B
Operating Income	-881.27M
Pretax Income	-1.38B
Net Income	-1.47B
EBITDA	-849.87M
EBIT	-881.27M
Loss Per Share	-24.33

Balance Sheet

The company has 3.98 billion in cash and 5.64 billion in debt, with a net cash position of -1.65 billion.

Cash & Cash Equivalents	3.98B
Total Debt	5.64B
Net Cash	-1.65B
Net Cash Per Share	n/a
Equity (Book Value)	-1.05B
Book Value Per Share	-17.15
Working Capital	256.06M

Cash Flow

In the last 12 months, operating cash flow was 348.56 million and capital expenditures -54.87 million, giving a free cash flow of 293.68 million.

Operating Cash Flow	348.56M
Capital Expenditures	-54.87M
Depreciation & Amortization	28.94M
Net Borrowing	-130.86M
Free Cash Flow	293.68M
FCF Per Share	n/a

Margins

Gross margin is 86.82%, with operating and profit margins of -18.92% and -31.67%.

Gross Margin	86.82%
Operating Margin	-18.92%
Pretax Margin	-29.53%
Profit Margin	-31.67%
EBITDA Margin	-18.25%
EBIT Margin	-18.92%
FCF Margin	6.31%

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.69%
Shareholder Yield	-4.69%
Earnings Yield	-1.95%
FCF Yield	0.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of 1.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	4